12.25
-0.015(-0.12%)
Currency In USD
| Previous Close | 12.26 |
| Open | 12.27 |
| Day High | 12.66 |
| Day Low | 12.24 |
| 52-Week High | 20.88 |
| 52-Week Low | 4.64 |
| Volume | 47,795 |
| Average Volume | 126,506 |
| Market Cap | 150.07M |
| PE | -2.57 |
| EPS | -4.76 |
| Moving Average 50 Days | 9.83 |
| Moving Average 200 Days | 8.91 |
| Change | -0.02 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $259.98 as of September 30, 2025 at a share price of $12.245. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $226.76 as of September 30, 2025 at a share price of $12.245.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity com
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
GlobeNewswire Inc.
Sep 16, 2025 12:00 PM GMT
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
GlobeNewswire Inc.
Jul 30, 2025 12:00 PM GMT
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical s